Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply.

Plevritis SK, Berry DA, Mandelblatt JS.

JAMA. 2018 Jun 12;319(22):2336. doi: 10.1001/jama.2018.4261. No abstract available.

PMID:
29896623
2.

GFPT2-Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma.

Zhang W, Bouchard G, Yu A, Shafiq M, Jamali M, Shrager JB, Ayers K, Bakr S, Gentles AJ, Diehn M, Quon A, West RB, Nair V, van de Rijn M, Napel S, Plevritis SK.

Cancer Res. 2018 Jul 1;78(13):3445-3457. doi: 10.1158/0008-5472.CAN-17-2928. Epub 2018 May 14.

PMID:
29760045
3.

DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity.

Anchang B, Davis KL, Fienberg HG, Williamson BD, Bendall SC, Karacosta LG, Tibshirani R, Nolan GP, Plevritis SK.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4294-E4303. doi: 10.1073/pnas.1711365115. Epub 2018 Apr 13.

4.

A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010.

Munoz DF, Xu C, Plevritis SK.

Med Decis Making. 2018 Apr;38(1_suppl):89S-98S. doi: 10.1177/0272989X17737508.

PMID:
29554473
5.

Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.

Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS; CISNET Breast Cancer Working Group members.

Med Decis Making. 2018 Apr;38(1_suppl):3S-8S. doi: 10.1177/0272989X17737507.

PMID:
29554472
6.

Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, Stout NK, van Ballegooijen M.

Med Decis Making. 2018 Apr;38(1_suppl):112S-125S. doi: 10.1177/0272989X17743244.

PMID:
29554471
7.

Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, Song J, Trentham-Dietz A, Plevritis SK, Moss SM, de Koning HJ.

Med Decis Making. 2018 Apr;38(1_suppl):140S-150S. doi: 10.1177/0272989X17718168.

PMID:
29554468
8.

Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling.

Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK.

Med Decis Making. 2018 Apr;38(1_suppl):9S-23S. doi: 10.1177/0272989X17700624.

PMID:
29554466
9.

Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment.

Munoz DF, Plevritis SK.

Med Decis Making. 2018 Apr;38(1_suppl):32S-43S. doi: 10.1177/0272989X17743236.

PMID:
29554464
10.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS.

JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130. Erratum in: JAMA. 2018 Feb 20;319(7):724.

11.

Distinguishing between CISNET model results versus CISNET models.

Berry DA, de Koning HJ, Lee SJ, Mandelblatt JS, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A; CISNET Breast Working Group Principal Investigators.

Cancer. 2018 Mar 1;124(5):1083-1084. doi: 10.1002/cncr.31150. Epub 2017 Dec 26. No abstract available.

PMID:
29278430
12.

Re: Think before you leap.

Han SS, Ten Haaf K, Hazelton WD, Jeon J, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK.

Int J Cancer. 2018 Apr 1;142(7):1507-1509. doi: 10.1002/ijc.31183. Epub 2017 Dec 28. No abstract available.

PMID:
29194597
13.

Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics.

Minamimoto R, Jamali M, Gevaert O, Echegaray S, Khuong A, Hoang CD, Shrager JB, Plevritis SK, Rubin DL, Leung AN, Napel S, Quon A.

Oncotarget. 2017 May 10;8(32):52792-52801. doi: 10.18632/oncotarget.17782. eCollection 2017 Aug 8.

14.

Non-Small Cell Lung Cancer Radiogenomics Map Identifies Relationships between Molecular and Imaging Phenotypes with Prognostic Implications.

Zhou M, Leung A, Echegaray S, Gentles A, Shrager JB, Jensen KC, Berry GJ, Plevritis SK, Rubin DL, Napel S, Gevaert O.

Radiology. 2018 Jan;286(1):307-315. doi: 10.1148/radiol.2017161845. Epub 2017 Jul 20.

PMID:
28727543
15.

Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model.

Han SS, Erdogan SA, Toumazis I, Leung A, Plevritis SK.

Cancer Causes Control. 2017 Sep;28(9):947-958. doi: 10.1007/s10552-017-0907-x. Epub 2017 Jul 12.

16.

Intestinal Enteroendocrine Lineage Cells Possess Homeostatic and Injury-Inducible Stem Cell Activity.

Yan KS, Gevaert O, Zheng GXY, Anchang B, Probert CS, Larkin KA, Davies PS, Cheng ZF, Kaddis JS, Han A, Roelf K, Calderon RI, Cynn E, Hu X, Mandleywala K, Wilhelmy J, Grimes SM, Corney DC, Boutet SC, Terry JM, Belgrader P, Ziraldo SB, Mikkelsen TS, Wang F, von Furstenberg RJ, Smith NR, Chandrakesan P, May R, Chrissy MAS, Jain R, Cartwright CA, Niland JC, Hong YK, Carrington J, Breault DT, Epstein J, Houchen CW, Lynch JP, Martin MG, Plevritis SK, Curtis C, Ji HP, Li L, Henning SJ, Wong MH, Kuo CJ.

Cell Stem Cell. 2017 Jul 6;21(1):78-90.e6. doi: 10.1016/j.stem.2017.06.014.

17.

Risk Stratification for Second Primary Lung Cancer.

Han SS, Rivera GA, Tammemägi MC, Plevritis SK, Gomez SL, Cheng I, Wakelee HA.

J Clin Oncol. 2017 Sep 1;35(25):2893-2899. doi: 10.1200/JCO.2017.72.4203. Epub 2017 Jun 23.

18.

Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.

Ten Haaf K, Jeon J, Tammemägi MC, Han SS, Kong CY, Plevritis SK, Feuer EJ, de Koning HJ, Steyerberg EW, Meza R.

PLoS Med. 2017 Apr 4;14(4):e1002277. doi: 10.1371/journal.pmed.1002277. eCollection 2017 Apr.

19.

Predictive radiogenomics modeling of EGFR mutation status in lung cancer.

Gevaert O, Echegaray S, Khuong A, Hoang CD, Shrager JB, Jensen KC, Berry GJ, Guo HH, Lau C, Plevritis SK, Rubin DL, Napel S, Leung AN.

Sci Rep. 2017 Jan 31;7:41674. doi: 10.1038/srep41674.

20.

The impact of overdiagnosis on the selection of efficient lung cancer screening strategies.

Han SS, Ten Haaf K, Hazelton WD, Munshi VN, Jeon J, Erdogan SA, Johanson C, McMahon PM, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK.

Int J Cancer. 2017 Jun 1;140(11):2436-2443. doi: 10.1002/ijc.30602.

21.

PS01.77: Risk-Stratification for Second Primary Lung Cancer: Topic: Medical Oncology.

Han S, Rivera GA, Cheng I, Gomez S, Plevritis SK, Wakelee H.

J Thorac Oncol. 2016 Nov;11(11S):S319-S320. doi: 10.1016/j.jtho.2016.09.112. Epub 2016 Oct 28. No abstract available.

22.

Visualization and cellular hierarchy inference of single-cell data using SPADE.

Anchang B, Hart TD, Bendall SC, Qiu P, Bjornson Z, Linderman M, Nolan GP, Plevritis SK.

Nat Protoc. 2016 Jul;11(7):1264-79. doi: 10.1038/nprot.2016.066. Epub 2016 Jun 16.

PMID:
27310265
23.

Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.

Gentles AJ, Bratman SV, Lee LJ, Harris JP, Feng W, Nair RV, Shultz DB, Nair VS, Hoang CD, West RB, Plevritis SK, Alizadeh AA, Diehn M.

J Natl Cancer Inst. 2015 Aug 18;107(10). pii: djv211. doi: 10.1093/jnci/djv211. Print 2015 Oct.

PMID:
26286589
24.

The prognostic landscape of genes and infiltrating immune cells across human cancers.

Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, Diehn M, West RB, Plevritis SK, Alizadeh AA.

Nat Med. 2015 Aug;21(8):938-945. doi: 10.1038/nm.3909. Epub 2015 Jul 20.

25.

Glioblastoma Multiforme: Exploratory Radiogenomic Analysis by Using Quantitative Image Features.

Gevaert O, Mitchell LA, Achrol AS, Xu J, Echegaray S, Steinberg GK, Cheshier SH, Napel S, Zaharchuk G, Plevritis SK.

Radiology. 2015 Jul;276(1):313. doi: 10.1148/radiol.2015154019. No abstract available.

26.

Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.

Green MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ, Irish J, Stehr H, Vicente-Dueñas C, Romero-Camarero I, Sanchez-Garcia I, Plevritis SK, Arber DA, Batzoglou S, Levy R, Alizadeh AA.

Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1116-25. doi: 10.1073/pnas.1501199112. Epub 2015 Feb 23.

27.

Pancancer analysis of DNA methylation-driven genes using MethylMix.

Gevaert O, Tibshirani R, Plevritis SK.

Genome Biol. 2015 Jan 29;16:17. doi: 10.1186/s13059-014-0579-8.

28.

Raising the bar for the U.S. Preventive Services Task Force.

de Koning HJ, Meza R, Plevritis SK.

Ann Intern Med. 2014 Oct 7;161(7):532-3. doi: 10.7326/L14-5019-3. No abstract available.

PMID:
25285549
29.

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju289. doi: 10.1093/jnci/dju289. Print 2014 Nov.

30.

CCAST: a model-based gating strategy to isolate homogeneous subpopulations in a heterogeneous population of single cells.

Anchang B, Do MT, Zhao X, Plevritis SK.

PLoS Comput Biol. 2014 Jul 31;10(7):e1003664. doi: 10.1371/journal.pcbi.1003664. eCollection 2014 Jul.

31.

Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling.

McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, ten Haaf K, Hazelton W, Holford TR, Jeon J, Clarke L, Kong CY, Choi SE, Munshi VN, Han SS, van Rosmalen J, Pinsky PF, Moolgavkar S, de Koning HJ, Feuer EJ.

PLoS One. 2014 Jun 30;9(6):e99978. doi: 10.1371/journal.pone.0099978. eCollection 2014.

32.

Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture.

Li X, Nadauld L, Ootani A, Corney DC, Pai RK, Gevaert O, Cantrell MA, Rack PG, Neal JT, Chan CW, Yeung T, Gong X, Yuan J, Wilhelmy J, Robine S, Attardi LD, Plevritis SK, Hung KE, Chen CZ, Ji HP, Kuo CJ.

Nat Med. 2014 Jul;20(7):769-77. doi: 10.1038/nm.3585. Epub 2014 May 25.

33.

Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features.

Gevaert O, Mitchell LA, Achrol AS, Xu J, Echegaray S, Steinberg GK, Cheshier SH, Napel S, Zaharchuk G, Plevritis SK.

Radiology. 2014 Oct;273(1):168-74. doi: 10.1148/radiol.14131731. Epub 2014 May 12. Erratum in: Radiology. 2015 Jul;276(1):313.

34.

Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.

Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, Choi SE, Jeon J, Han SS, Munshi V, van Rosmalen J, Pinsky P, McMahon PM, de Koning HJ, Feuer EJ, Hazelton WD, Plevritis SK.

Cancer. 2014 Jun 1;120(11):1713-24. doi: 10.1002/cncr.28623. Epub 2014 Feb 27.

35.

Identification of ovarian cancer driver genes by using module network integration of multi-omics data.

Gevaert O, Villalobos V, Sikic BI, Plevritis SK.

Interface Focus. 2013 Aug 6;3(4):20130013. doi: 10.1098/rsfs.2013.0013. Erratum in: Interface Focus. 2014 Jun 6;4(3):20140023.

36.

Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.

de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J, Choi SE, Pinsky PF, Berrington de Gonzalez A, Berg CD, Black WC, Tammemägi MC, Hazelton WD, Feuer EJ, McMahon PM.

Ann Intern Med. 2014 Mar 4;160(5):311-20. doi: 10.7326/M13-2316.

37.

NF-κB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism.

Nair VS, Gevaert O, Davidzon G, Plevritis SK, West R.

Lung Cancer. 2014 Feb;83(2):189-96. doi: 10.1016/j.lungcan.2013.11.001. Epub 2013 Nov 13.

38.

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.

Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, Warnke RA, Natkunam Y, Han SS, Yuen A, Plevritis SK, Advani RH.

Blood. 2013 Aug 8;122(6):981-7. doi: 10.1182/blood-2013-03-491514. Epub 2013 Jun 18.

39.

Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.

Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, Kela I, Hopmans ES, Myklebust JH, Ji H, Plevritis SK, Levy R, Alizadeh AA.

Blood. 2013 Feb 28;121(9):1604-11. doi: 10.1182/blood-2012-09-457283. Epub 2013 Jan 7.

40.

Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.

Schackmann EA, Munoz DF, Mills MA, Plevritis SK, Kurian AW.

Fam Cancer. 2013 Mar;12(1):65-73. doi: 10.1007/s10689-012-9577-8.

41.

TreeVis: a MATLAB-based tool for tree visualization.

Qiu P, Plevritis SK.

Comput Methods Programs Biomed. 2013 Jan;109(1):74-6. doi: 10.1016/j.cmpb.2012.08.008. Epub 2012 Oct 1.

42.

CytoSPADE: high-performance analysis and visualization of high-dimensional cytometry data.

Linderman MD, Bjornson Z, Simonds EF, Qiu P, Bruggner RV, Sheode K, Meng TH, Plevritis SK, Nolan GP.

Bioinformatics. 2012 Sep 15;28(18):2400-1. doi: 10.1093/bioinformatics/bts425. Epub 2012 Jul 10.

43.

Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results.

Gevaert O, Xu J, Hoang CD, Leung AN, Xu Y, Quon A, Rubin DL, Napel S, Plevritis SK.

Radiology. 2012 Aug;264(2):387-96. doi: 10.1148/radiol.12111607. Epub 2012 Jun 21.

44.

Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer.

Nair VS, Gevaert O, Davidzon G, Napel S, Graves EE, Hoang CD, Shrager JB, Quon A, Rubin DL, Plevritis SK.

Cancer Res. 2012 Aug 1;72(15):3725-34. doi: 10.1158/0008-5472.CAN-11-3943. Epub 2012 Jun 18. Erratum in: Cancer Res. 2012 Sep 15;72(18):4870-1.

45.

A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.

Sigal BM, Munoz DF, Kurian AW, Plevritis SK.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77. doi: 10.1158/1055-9965.EPI-12-0149. Epub 2012 May 3.

46.

Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition.

Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P.

Mol Cancer Ther. 2012 May;11(5):1071-81. doi: 10.1158/1535-7163.MCT-11-0852. Epub 2012 Mar 12.

47.

Online tool to guide decisions for BRCA1/2 mutation carriers.

Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.

J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.

48.

Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model.

Lin RS, Plevritis SK.

Cancer Causes Control. 2012 Jan;23(1):175-85. doi: 10.1007/s10552-011-9866-9. Epub 2011 Nov 25.

49.

Modeling the impact of population screening on breast cancer mortality in the United States.

Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, Feuer EJ.

Breast. 2011 Oct;20 Suppl 3:S75-81. doi: 10.1016/S0960-9776(11)70299-5.

50.

Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.

Choi PS, van Riggelen J, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ, Plevritis SK, Felsher DW.

Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17432-7. doi: 10.1073/pnas.1107303108. Epub 2011 Oct 3.

Supplemental Content

Loading ...
Support Center